Bioaminex does not sell products directly. Everything begins with lab work and a licensed physician. Please confirm you understand:
Peptide therapies may involve compounds that are prescription-only or investigational. Nothing here should be used without physician supervision and appropriate laboratory monitoring.
An FDA-approved peptide for low sexual desire in women — and a compound with real, well-documented side effects worth understanding before starting.
PT-141 is one of the more genuinely FDA-approved compounds on this page, with a real approved indication. It's also one with the most well-documented, common side effects — worth knowing plainly before you consider it.
PT-141 (bremelanotide) was FDA-approved in June 2019 under the brand name Vyleesi for hypoactive sexual desire disorder in premenopausal women, following two Phase 3 trials and over a decade of development. Unlike PDE5 inhibitors like sildenafil (Viagra), which work on blood flow, PT-141 works centrally — in the brain — to affect desire itself.
PT-141 activates melanocortin receptors (specifically MC4R) in the hypothalamus, a brain region involved in regulating sexual desire and arousal. This is a fundamentally different pathway than erectile-dysfunction medications, which act peripherally on blood vessels — which is why the two are sometimes discussed as complementary rather than interchangeable.
Its FDA approval rests on two identical Phase 3 trials in premenopausal women with HSDD, showing improved desire and reduced distress compared to placebo. Off-label use in men (for erectile function or libido) and in postmenopausal women is more common in practice than the label indication, and rests on a smaller, less rigorous evidence base than the approved use.
This is genuinely important: nausea affected roughly 40% of women in trials, along with flushing, headache, and injection-site reactions, and temporary blood pressure increases can occur. About 1% of trial participants developed focal skin hyperpigmentation — usually on the face, gums, or breasts — which was reversible in most but not all cases over weeks to months. It's not appropriate for people with uncontrolled cardiovascular disease, and the pigmentation and blood-pressure effects are exactly the kind of thing a provider needs to discuss with you directly before you start, not discover afterward.
PT-141 has a real FDA approval and real trial evidence behind it — and real, common side effects that are more prominent than most peptides discussed here. It's a legitimate option worth an honest conversation with a provider, specifically because the side-effect profile is well documented enough that you deserve to hear it plainly before you start.
This article is for educational purposes only and is not medical advice. It does not establish a provider-patient relationship. FDA-approval status and clinical information are summarized in general terms and may change; consult a licensed healthcare provider and current prescribing information before making any medical decision. Bioaminex does not sell or dispense PT-141 or any medication.